Benitec Biopharma (BNTC) Projected to Announce Quarterly Earnings on Friday

Benitec Biopharma (NASDAQ:BNTC) is anticipated to post its Q1 2027 results before the market opens on Friday, November 13th. Analysts expect Benitec Biopharma to announce earnings of ($0.2686) per share for the quarter. Individuals can check the company’s upcoming Q1 2027 earnings report for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

Benitec Biopharma (NASDAQ:BNTC) last announced its earnings results on Monday, September 14th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.26). On average, analysts expect Benitec Biopharma to post ($1.35) EPS for the current fiscal year and ($1.55) EPS for the next fiscal year.

Benitec Biopharma Stock Down 6.0%

BNTC opened at $9.28 on Wednesday. The company has a market cap of $323.77 million, a price-to-earnings ratio of -9.47 and a beta of 0.26. Benitec Biopharma has a 52-week low of $7.89 and a 52-week high of $14.39. The firm’s fifty day simple moving average is $9.87 and its two-hundred day simple moving average is $11.44.

Wall Street Analysts Forecast Growth

BNTC has been the topic of a number of research reports. Raymond James Financial started coverage on shares of Benitec Biopharma in a research note on Friday, October 23rd. They issued an “outperform” rating and a $14.00 price target on the stock. Royal Bank Of Canada upgraded Benitec Biopharma to an “outperform” rating in a research note on Tuesday, September 15th. HC Wainwright reissued a “buy” rating on shares of Benitec Biopharma in a report on Monday, November 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Thursday, October 15th. Finally, Wedbush lifted their price target on Benitec Biopharma from $16.00 to $17.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 15th. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Benitec Biopharma currently has a consensus rating of “Moderate Buy” and an average target price of $22.00.

About Benitec Biopharma

Benitec Biopharma Inc. (NASDAQ:BNTC) is a clinical-stage biotechnology company developing genetic medicines based on its proprietary DNA-directed RNA interference (ddRNAi) technology. The platform is designed to enable cells to produce small hairpin RNA molecules that can selectively reduce the expression of disease-causing genes, potentially providing longer-lasting gene silencing than conventional RNA-based approaches. The company’s lead program is BB-301, an investigational gene therapy being developed for oculopharyngeal muscular dystrophy type 1 (OPMD1), a rare inherited disorder that affects muscles involved in swallowing and movement.